Oversized devices are becoming more common as time goes on, which suggests operators are growing increasingly comfortable with this treatment choice.

The Impella RP System is still associated with significant benefits, the FDA said, but there are certain high-risk patients who should no longer be eligible for treatment.

A randomized study of more than 450 patients with persistent atrial fibrillation is now underway. All patients have been treated, and their outcomes will be tracked for 12 months. 

This latest recall involves the device's driveline boot cover, which “can become stiff over time” and cause problems for clinicians. There have been 33 complaints since 2017 related to the issue.

Researchers examined data from more than 900 patients, presenting their findings in the Journal of the American Heart Association.

The authors of a new commentary in the American Journal of Cardiology argued that well-balanced plant-based diets are good for the heart and good for society as a whole. 

Read our recap of some of the biggest FDA-related stories that impacted cardiology in the last month.

The ACC is especially excited to see what VR training can do to bring minimally invasive interventional procedures to more and more patients throughout the United States.